International Stem Cell Corporation (ISCO.OB) is a California company that has developed breakthrough human stem cell lines that promise to eliminate the rejection of transplanted cells by the patient’s immune system. ISCO’s technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs without the transfer of foreign DNA. This methodology offers the potential to create the first true “Stem Cell Bank” and also addresses critical ethical issues by eliminating the need to use fertilized embryos. ISCO also produces and sells specialized cells and growth media worldwide for therapeutic research.
|
